Empagliflozin is known for its beneficial effects on cardiovascular and renal outcomes. However, its impact on diabetic retinopathy (DR) progression in type 2 diabetes (T2D) patients remains uncertain. A study has investigated the association between empagliflozin and DR progression and nonproliferative DR (NPDR) by analyzing insurance claims data from over 30,000 T2D patients.
Over an eight-month follow-up period, the study found that empagliflozin initiation reduced the risk of DR progression by 22% in T2D patients with a history of NPDR compared to initiating dipeptidyl peptidase-4 inhibitor therapy. However, empagliflozin was not associated with incidents of NPDR in T2D patients without a DR history. These findings suggest that empagliflozin’s role in reducing DP progression may be valuable when evaluating the risks and benefits of different anti-diabetic drugs for T2D patients.…
